Table 1. Characteristics and antiosteoporotic use of the study population a .
| n (%) | Treated (%) | p b | ||
|---|---|---|---|---|
| Age | 50–54 years | 111 (13.5) | 16.2 | 0.27 |
| 55–59 years | 156 (18.9) | 21.2 | ||
| 60–64 years | 173 (21.0) | 23.7 | ||
| 65–69 years | 170 (20.6) | 27.7 | ||
| 70–74 years | 144 (17.5) | 19.4 | ||
| 75+ years | 70 (8.5) | 20.0 | ||
| Educational level | No studies | 155 (22.1) | 20.0 | 0.81 |
| Primary | 350 (49.9) | 22.6 | ||
| Secondary/Univers. | 196 (28.0) | 21.9 | ||
| BMI | <20 | 14 (1.7) | 35.7 | 0.006 |
| 20.0–24.9 | 173 (21.0) | 27.8 | ||
| 25.0–29.9 | 349 (42.4) | 24.4 | ||
| ≥30 | 287 (34.9) | 15.0 | ||
| Menopause age ≤40 y | No | 754 (91.6) | 20.2 | <0.001 |
| Yes | 69 (8.4) | 42.0 | ||
| BMD | Normal | 168 (20.4) | 16.1 | 0.001 |
| Osteopenia | 423 (51.4) | 19.9 | ||
| Osteoporosis | 232 (28.2) | 30.2 | ||
| Parental history of osteoporotic fracture | No | 659 (80.0) | 22.0 | 0.96 |
| Yes | 165 (20.0) | 21.8 | ||
| Prior non-vertebral osteoporotic fracture | No | 782 (94.9) | 21.4 | 0.07 |
| Yes | 42 (5.1) | 33.3 | ||
| Morphometric vertebral fracture | No | 680 (84.4) | 21.0 | 0.002 |
| Mild | 76 (9.4) | 18.4 | ||
| Mod/Severe | 50 (6.2) | 42.0 | ||
| Glucocorticoid treatment | No | 773 (93.8) | 21.5 | 0.19 |
| Yes | 51 (6.2) | 29.4 | ||
| Other drugs that decrease bone mass | No | 756 (91.8) | 22.0 | 0.99 |
| Yes | 68 (8.3) | 22.1 | ||
| Smoking | No | 788 (95.6) | 22.1 | 0.71 |
| Yes | 36 (4.4) | 19.4 | ||
| Dietary calcium intake | ≥500mg/day | 761 (92.4) | 22.3 | 0.37 |
| <500mg/day | 63 (7.7) | 17.5 | ||
| Other secondary causes of osteoporosis | No | 726 (88.1) | 21.9 | 0.90 |
| Yes | 98 (11.9) | 22.5 | ||
| FRAX 10-years risk hipfracture c | ≤1 | 545 (66.1) | 19.3 | 0.02 |
| 1–3 | 170 (20.6) | 28.8 | ||
| >3 | 109 (13.2) | 24.8 | ||
| TOTAL [unweighted] | 824(100.0) | 22.0 |
BMI, body mass index; BMD, bone mass density.
a n = 824; missing data: studies (123), vertebral fracture (18), BMI (1), BMD (1).
b χ2 test.
c FRAX scores were calculated using the BMD results.
Treatment prevalence weighted to represent the age-structure of women of 50 and over in
Valencia was 20.9% (95%CI: 17.6–24.4).